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Abstract
Background: YM529 is a newly developed nitrogen-containing bisphosphonate (BP) classified as
a third-generation BP that shows a 100-fold greater potency against bone resorption than
pamidronate, a second-generation BP. This agent is, therefore expected to be extremely useful
clinically for the treatment of osteoporosis and hypercalcemia. Recently, YM529 as well as other
third-generation BPs have also been shown to exert anti-tumor effects against various types of
cancer cells both in vitro or/and in vivo. In this study, we investigate the anti-tumor effect of YM529
on non-small cell lung cancer (NSCLC).
Methods: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23,
H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125,
squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition
concentration 50 % (IC50) values. YM529 induced apoptosis of NCI-H1819 was examined by DNA
fragmentation of 2 % agarose gel electrophoresis and flowcytometric analysis (sub-G1 method). We
examined where YM529 given effect to apoptosis of NSCLC cells in signaling pathway of the
mevalonate pathway by western blotting analysis.
Results: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a
dose-dependent manner and their IC50 values were 2.1 to 7.9 μM and YM529 induced apoptosis
and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of
phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
Conclusion: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell
lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one
of therapeutic options for NSCLC.
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Background
Lung cancer is the leading cause of death from cancer
worldwide. Approximately 80% of lung cancers can be
histologically classified as non-small cell lung cancers
(NSCLCs). The majority of patients presents with locally
advanced (37%) or metastatic (38%) disease at the time
of diagnosis [1]. Despite advances in chemotherapy, the
average 5-year survival rate of the patients with advanced
NSCLC remains extremely poor [1]. Thus, newer agents
must be developed to establish an effective therapeutic
strategy against NSCLC.
Bisphosphonates (BPs) are structural analogues of pyro-
phosphoric acid, which is a biomedical component. Sev-
eral studies have shown that BPs exert direct anti-tumor
effects on a variety of human tumor cell lines (myeloma,
breast, prostate, pancreas) in vitro in a concentration- and
time-dependent manner [2-13]. BPs have a common basic
structure and different substituents at the one of two cov-
alentlybounded side-chain attached to the germinal car-
bon, which strongly influence their pharmacologic
properties [14]. The so-called second- or third-generation
BPs contain nitrogen and inhibit protein prenylation in
osteoclasts to induce apoptosis [14-17]. YM529 (1-
Hydroxy-2-imidazo [1,2-a]pyridin-3-yl) ethylidene
bisphosphonic acid monohydrate is a newly developed
nitrogen-containing BP classified as a third-generation BP
that shows a 100-fold greater potency against bone
resorption than pamidronate, a second-generation BP.
This agent is, therefore expected to be extremely useful
clinically for the treatment of osteoporosis and hypercal-
cemia.
Recently, YM529 as well as other third-generation BPs
have also been shown to exert anti-tumor effects against
various types of cancer cells both in vitro or/and in vivo
[7,13,18-22]. However, study that evaluated the effect of
BPs including YM529 on NSCLC has been limited and the
effect of zoledronic acid on only one cell line was exam-
ined [23].
In this study, we examined the effects of YM529 on 8
NSCLC cell lines to investigate the potential usefulness of
YM529 as a therapeutic agent against NSCLC.
Methods
Reagents and cell lines
YM529 was kindly provided by Astellas Pharmaceuticals
Co., Ltd. (Tokyo, Japan). YM529 was diluted in 10 mM of
concentration and stored at -20°C for in vitro experiment.
Eight human NSCLC cell lines (adenocarcinoma; NCI-
H23, NCI-H1819, NCI-H2009, HCC44, A549, squamous
cell carcinoma; NCI-H157, adenosquamous cell carci-
noma; NCI-H125, large cell carcinoma; NCI-H1299, there
are involved all type of NSCLC) were kindly provided by
Dr. Adi F. Gazdar (University of Texas Southwestern Med-
ical Center, Dallas, USA). All 8 cell lines were maintained
at 37°C in a fully humidified atmosphere of 5% CO2 in
air as suspension cultures in RPMI-1640 medium (Sigma
chemical co. St. Louis, MO) supplemented with 10% fetal
bovine serum (FBS) and 100 U/ml penicillin and 100 μg/
ml streptomycin (Sigma chemical co. St. Louis, MO).
Determination of cell proliferation
Cell proliferation was determined by a modified MTS
assay with CellTiter 96® AQueous One Solution Reagent
(Promega, Madison, WI). NSCLC cells were seeded on 96-
well flat-bottomed tissue culture plates(Becton Dickin-
son, San Jose, CA) at a concentration of 5 × 103 cells/well
with complete culture medium and allowed to adhere to
the plate overnight. Then the cells were incubated in the
presence of each concentration of 0(control), 0.01, 0.1, 1,
5, 10, 20, 50, 100, 200 μM of YM529 for another 72 hours
at 37°C in a humidified atmosphere of 5% CO2 in air.
After treatment, 20 μl of CellTiter 96® AQueous One Solu-
tion Reagent were dropped into each well of plates. After
90 minutes incubation, the optical densities (OD) of
these samples were directly measured using an Immuno
Mini NJ-2300 (Nalge Nunc International KK, NY, USA)
and reference wavelength of 490 nm. The OD of control
samples was regarded as 100. Each condition was per-
formed with 8 wells and each experiment was repeated
twice. The anti-proliferative activities of YM529 are shown
in terms of IC50s.
Electrophoresis of DNA fragment
NCI-H1819 cells were treated with concentrations 0 (neg-
ative control) and 10, 100 μM of YM529 for 48 hours. As
positive control, NCI-H1819 was incubated for 24 hours
after UV light (10 mJ/cm2) irradiation. Genomic DNA was
isolated by digestion with proteinase K followed by phe-
nol:chloroform (1:1) extraction and ethanol precipitation
from cell lines and primary tumor [24].
DNA and DNA marker of TrackIt 1 kb Plus Ladder (Invit-
rogen co. Carlsbad, CA, USA) were separated on 2 % aga-
rose gels.
Flow cytometric analysis of apoptosis
Subconfluent NCI-H1819 cells were cultured in 60 mm
dishes with concentrations 0(control), 10 and 100 μM of
YM529 for 24 hours. Cells were trypsinized, fixed in 70 %
iced-cold ethanol, and stored at -20°C for 72 hours. After
fixation, cells were suspended in 100 μl phosphate-citrate
buffer (0.19 M Na2HPO4, 4 mM citric acid) and incubated
for 30 min at room temperature and resuspended in 1 ml
of PBS containing 10 μg/ml of propidium iodide (PI) and
10 μg/ml of RNase A. The PI-stained cell samples were
analyzed using FACSCalibur (Becton-Dickinson San Jose,BMC Cancer 2007, 7:8 http://www.biomedcentral.com/1471-2407/7/8
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CA) and data analysis for the population of cells in sub-
G1, G1, S and G2/M phase of the cell cycle was performed
with CELLQuest (Becton-Dickinson San Jose, CA). Cells
undergoing apoptosis were determined as a percentage of
cells with sub-G1 population.
Western blotting analysis
Subconfluent NCI-H1819 cells were cultured in 60 mm
dishes with concentrations 0(control), 10 and 100 μM of
YM529 for 24 hours. Equal amount of protein (10 μg)
were separated by SDS-PAGE and transferred to PVDF
membranes. The membranes were probed with mono-
clonal anti-Ras (Becton Dickinson biosciences, San Jose,
CA), goat polyclonal anti-unprenylated Rap1A antibody
(Santa Cruz Biotechnology inc., Santa Cruz, CA), anti-
ERK1/2 (Sigma chemical co. St. Louis, MO), anti-phos-
pho-ERK1/2, anti-Akt, anti-phospho-Akt, β-actin (Cell
Signaling Technology Inc., MA, US) antibodies, and then
with goat anti-rabbit, goat anti-mouse and rabbit anti-
goat IgG-HRP coupled to horseradish peroxidase conju-
gated secondary antibodies (Santa Cruz biotechnology
inc., Santa Cruz, CA), after which the membranes were
developed by ECL Plus Western Blotting Detection Rea-
gents (Amersham Biosciences UK Limited, Buckingham-
shire, UK).
Results
YM529 inhibited growth of NSCLC cell lines
To evaluate the growth inhibitory effect of YM529 on
NSCLC cell lines, we used the MTS assay and calculated
the IC50 values. YM529 inhibited cell proliferation in a
concentration-dependent manner in all the 8 cell lines
(Fig. 1). The IC50 values for the 8 NSCLC cell lines ranged
from 2.1 to 7.9 μM. Because YM529 inhibited the prolif-
eration of NCI-H1819 most strongly among 8 NSCLC cell
lines (Fig. 1), for following experiments, this cell line
(NCI-H1819) was used as a model line.
Induction of apoptosis
To confirm that YM529 caused apoptosis, we examined
the fragmentation status of genomic DNA in NCI-H1819
cells treated with drug (Fig. 2). DNA was extracted and
electorophoresis was performed. As shown in Fig. 3, short
fragments of DNA were observed in the cell cultures
treated with 10 and 100 μM of YM529, similar to the
result in the positive control which was represented by
NCI-H1819 cells exposed to UV light irradiation at 10 mJ/
cm2 (Fig. 2).
Cell cycle distribution
To elucidate the molecular mechanism underlying the
anti-tumor activity of YM529, we examined the cell cycle
distribution in NCI-H1819 cells by flow cytometric anal-
ysis after PI staining. No significant changes in the S and
G2/M phase of the cell cycle was observed for any concen-
tration of YM529. However, an increase in the percentage
of cells in the G1 phase was observed in a YM529-concen-
tration-dependent manner (Fig. 3). While there were no
significant changes in the population of cells in the sub-
G1 phase in the cells subjected to no treatment or treated
with 1 or 10 μM of YM529 (4.2, 3.0, and 3.9 %, respec-
tively), a significant increase in the population of cells in
the sub- G1 phase was observed in the cells treated with
100 μM of YM529 (21.0%) (Fig. 3). These results suggest
that YM529 induced cell cycle arrest at the G1 phase and
consequently stimulated apoptosis in the NCI-H1819 cell
line.
Down-regulation of anti-apoptosis
To identify the molecules involved in the YM529-induced
cell cycle arrest and apoptosis, we examined the protein
expression status of members of the small GTP-binding
protein related cascade that YM529 was assumed to
inhibit in order to cause apoptosis. Western blotting anal-
ysis showed that anti-Ras or anti-unprenylated Rap1A
antibody recongnized the unprenylation of Ras or Rap1A
in a dose-dependent manner of YM529 (Fig. 4). In addi-
tion, the phospho-ERK1/2 protein was down-regulated by
YM529 treatment. (Fig. 4). These results suggested that
YM529 inhibited ERK1/2 pathway via inhibition of far-
nesylation and/or geranylgeranylation of GTP-binding
proteins. There were no significant changes in the expres-
sion of either Akt or phospho-Akt in the cells.
Discussion
Our studies showed that YM529 directly inhibited cell
proliferation in NSCLC cell lines. The IC50  values of
YM529 for the 8 cell lines examined ranged from 2.1 to
7.9 μM. While the effects of third-generation BPs, includ-
ing YM529, YM175 and zoledronic acid, have been exam-
ined in several kinds of human cancers, this is the first
study to shown that the third-generation BPs may also be
effective against NSCLC [9-13,22,23]. YM529 is as potent
as zoledronic acid at inhibiting bone resorption in vivo,
despite the difference in the substituent at the covalently-
bounded side-chain. In relation to the effects of these
agents on human cancer, YM529 and zoledronic acid
have been reported to show similar cytotoxic effects
against luekemic cell lines, with an IC50 value of 22–73
μM [19], which also indicates that the IC50  value of
YM529 for NSCLC was lower than that for leukemic cell
lines. Indeed, the IC50 value for leukemic cells in our study
was similar to that reported previously, which also indi-
cated that our assay was appropriate. In the case of lung
cancer, the effect of zoledronic acid was examined against
12 small-cell lung cancer (SCLC) cell lines; it was shown
that the agent exerted anti-proliferative effect in of the 8
cell lines with IC50 values in the range of 13–30 μM,
whereas the remaining cell lines were resistant to
zoledronic acid [22]. Taking into account this findingBMC Cancer 2007, 7:8 http://www.biomedcentral.com/1471-2407/7/8
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Direct effect of YM529 on 8 cell lines of NSCLC cell lines H23 (A), H1299 (B), NCI-H1819 (C), NCI-H2009 (D), H44 (E),  A549 (F), NCI-H125 (G), NCI-H157 (H) Figure 1
Direct effect of YM529 on 8 cell lines of NSCLC cell lines H23 (A), H1299 (B), NCI-H1819 (C), NCI-H2009 (D), H44 (E), 
A549 (F), NCI-H125 (G), NCI-H157 (H). Cells were incubated with concentration of 0(control), 0.01, 0.1, 1, 5, 10, 20, 50, 100 
μM of YM529 for 72 hours exposure, and cell proliferation was determined by MTS assay. Date represent cell number during 
treatment relative to control untreated cells (100%). The averages: bars, SD.
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with our own, it appears that third-generation BPs may be
more effective against NSCLC than against SCLC.
In regard to the mechanism of action of nitrogen-contain-
ing BPs, including YM529, it is thought that they inhibit
the activity of farnesyl diphosphate (FPP) synthase and
geranylgeranyl diphosphate (GGPP) synthase which
cause activation of FPP and GGPP, respectively. Since FPP
and GGPP activation cause prenylation of small GTP-
binding proteins including Ras resulting in anti-apopto-
sis, inhibition of their activation by YM529 induces cellu-
lar apoptosis [25-29]. Indeed, YM529 induced
unprenylation of Ras and Rap1A resulting in down-regu-
lation of ERK1/2 phosphorylation in NCI-H1819 cells
despite absence of any effect on ERK1/2 expression.
Recent reports have shown that inhibition of the ERK1/2
pathway reduces cycline-CDK2 kinase activity and subse-
quent G1 arrest indicating apoptosis [30,31]. Our flow
cytometirc analysis of the NCI-H1819 cell line confirmed
the increase of the G1 population with YM529 treatment.
Taking together these findings, it is speculated that YM529
exerts its anti-proliferative effect against NSCLC by induc-
tion of cellular apoptosis through the small GTP-binding
proteins associated signal transduction pathway.
Several studies have indicated the usefulness of the com-
bined use of BPs with other cytotoxic agents [12,22,32].
Matsumoto et al. reported that zoledronic acid aug-
mented the anti-proliferative activity of paclitaxel, etopo-
side, cisplatinum, irinotecan and imatinib in SCLC cells
DNA fragmentation induced by treatment of YM529 (10, 100 μM) and UV irradiation Figure 2
DNA fragmentation induced by treatment of YM529 (10, 100 μM) and UV irradiation. DNA of UV irradiation (10 mJ/cm2) was 
positive control. DNAs of no treatment (negative control), positive control, treatment of 10, 100 μM YM529 were fraction-
ated through a 2 % agarose gel and stained with ethidium bromide. Lane M in panel is size markers.
M
Positive
Control
UV10,000J NT
YM529
10Ǵ Ǵ Ǵ ǴM
YM529
100Ǵ Ǵ Ǵ ǴMBMC Cancer 2007, 7:8 http://www.biomedcentral.com/1471-2407/7/8
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[22]. In addition, cytotoxic agents, including cisplatin,
gemcitabine, and taxol shown enhanced anti-tumor effect
when combined with a farnesyltransferase inhibitor (FTI-
2148) or geranylgeranyltransferase inhibitor (GGTI-
2154) in mice bearing A549 cells [32]. Because YM529 is
assumed to inhibit farnesylation and geranylgeranylation
synthase as mentioned, combined treatment with YM529
and these cytotoxic agents may be a more effective treat-
ment strategy than monotherapy in the case of NSCLC as
well.
Conclusion
Our study demonstrated that YM529 showed direct anti-
tumor effect on NSCLC cell lines in vitro and induced
apoptosis and G1 arrest cell cycle through down regula-
tion of phospholyration of ERK1/2. These findings sup-
port the possibility that third-generation BPs including
YM529 can be one of therapeutic options for NSCLC.
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Cell cycle analysis of NSCLC cells treated with YM529 Figure 3
Cell cycle analysis of NSCLC cells treated with YM529. NCI-H1819 cells were stained with PI after 24 hours exposure of no 
treatment (control), 1, 10 100 μM of YM529. There were analyzed by flow cytometry. DNA histgram of control (A), YM529 1 
μM (B), YM529 10 μM (C), YM529 100 μM (D) were shown. The percentages of the cell population in the different phase (sub-
G1, G1, S, G2/M) of cell cycle were analyzed by CELLQuest. Percentages of apoptosis were measured as sub-G1 content of his-
togram. Similar results were obtained in three independent experiments.
control YM529 1Ǵ Ǵ Ǵ ǴM YM529 10Ǵ Ǵ Ǵ ǴM YM529 100Ǵ Ǵ Ǵ ǴM
C YM529 1˩ ˩ ˩ ˩ M YM529 10˩ ˩ ˩ ˩ M YM529 100˩ ˩ ˩ ˩ M
Sub-G1 4.2 3 3.9 21
G1 75.1 75 65.6 43.6
S 8.4 10 8.7 17.3
G2/M 12.3 12 21.8 18.1
The population of cell cycle in NCI-H1819 (%)BMC Cancer 2007, 7:8 http://www.biomedcentral.com/1471-2407/7/8
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